Non-platinum based combination chemotherapy: Phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan

Seminars in Oncology

Volumn 28, Issue 3 SUPPL. 9, 2001, Pages 15-20

  Rigas, James R ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034978935     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(01)90220-9     Document Type: Article

References (28)

1. Chemotherapy in NSCLC: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life
3. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer
4. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome
5. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group study
6. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer
7. A prospective randomized trial of docetaxel (taxotere) versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy
8. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with a platinum containing agent
9. Phase I study of docetaxel and gemcitabine combination chemotherapy in chemotherapy naive patients with advanced or metastatic non-small cell lung cancer
10. Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy in patients with metastatic non-small cell lung cancer
11. Phase I and pharmacokinetic study of docetaxel and gemcitabine in patients with non-small cell lung cancer
12. Combination of docetaxel and gemcitabine in the treatment of advanced non-small cell lung cancer
13. Weekly administration of docetaxel (taxotere): Summary of clinical data
14. Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial
15. Docetaxel (taxotere) plus gemcitabine (gemtro). A new combination in the treatment of patients with advanced non-small cell lung cancer. A preliminary analysis
16. Docetaxel and gemcitabine in metastatic non-small cell lung cancer. A phase II study. Preliminary feasibility report
17. Treatment of advanced non-small cell lung carcinomas with taxotere, gemcitabine and G-CSF
18. A phase II study of docetaxel (D) and gemcitabine (G) combination in patients (pts) with non-small cell lung cancer (NSCLC)
19. Gemcitabine (G) followed by 2nd line docetaxel (D) is feasible in advanced NSCLC: Results from a randomized phase II study
20. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
21. First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine
22. Interim results of a phase II study of docetaxel (taxotere) and vinorelbine in chemotherapy naive patients with advanced non-small cell lung cancer
23. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer
24. First-line therapy of taxotere (T) and navelbine (N) in patients with advanced non-small cell lung cancer (NSCLC): A phase II study
25. Phase I dose-finding and pharmacokinetic (PK) study of docetaxel (D) in combination with irinotecan (I) in advanced solid tumors
26. Phase I study of docetaxel (DOC) and irinotecan (CPT-11) for previously untreated advanced non-small cell lung cancer (NSCLC)
27. Phase I dose escalation trial of weekly docetaxel (D) plus irinotecan (I) in patients with advanced solid tumors
28. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC): A West Japan Thoracic Oncology Group (WJTOG) study